MycoLogics, Inc. To Develop A High Throughput Screen Used To Identify Antifungal Drugs
10/19/2005 5:10:44 PM
MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, today announced award of a Phase I SBIR grant by the Department of Health and Human Services to isolate a new class of compounds by disrupting beta(1,3)-glucan synthesis using a novel assay. The beta(1,3)-glucan polymer is an essential component for fungal growth, it is found in fungi not in humans and is a validated FDA-approved clinical target for antifungals. The patentable assay is scaleable from low throughput to high throughput.
comments powered by